SCHEMBL5756089

SCHEMBL5756089

COc1ccc(O)c(-c2nc3ccc(N)cc3s2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.62
MAPT P10636 3/20 0.60
NPC1 O15118 3/20 0.60
THRB P10828 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
KDM4E B2RXH2 2/20 0.60
GAA P10253 2/20 0.60
RAB9A P51151 2/20 0.60
MEN1 O00255 1/20 0.60
POLB P06746 1/20 0.60
ALOX15 P16050 1/20 0.60
CASP1 P29466 1/20 0.60
SNCA P37840 1/20 0.60
CASP7 P55210 1/20 0.60
KMT2A Q03164 1/20 0.60
HSD17B10 Q99714 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130200 0.83 APP (0.57) APPMAPTNPC1KDM4EGAA
SCHEMBL30386590 0.83 MAPT (0.64) APPMAPTNPC1THRBSMN1; SMN2
SCHEMBL5429408 0.83 MAPT (0.64) APPMAPTNPC1THRBSMN1; SMN2
SCHEMBL5756169 0.82 KDM4E (0.53) APPMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL5761063 0.81 NPC1 (0.53) APPMAPTNPC1SMN1; SMN2GAA
SCHEMBL1982972 0.81 APP (0.67) APPGAACYP1A2CYP3A4CYP2C19
SCHEMBL5906664 0.80 APP (0.84) APPMAPTNPC1THRBSMN1; SMN2
SCHEMBL4730485 0.80 APP (0.66) APPGAACYP1A2CYP3A4CYP2C19
SCHEMBL229456 0.78 APP (0.68) APPGAACYP1A2CYP3A4CYP2C19
SCHEMBL1977100 0.77 APP (1.00) APPMAPTNPC1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539723-B1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2006-05-24 EP claimed
US-20060106015-A1 Novel use of benzothiazole derivatives ASTRAZENECA (SE) 2006-05-18 US claimed
CN-1675189-A New use of benzothiazole derivatives ASTRAZENECA AB (SE) 2005-09-28 CN claimed
EP-1539723-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES AstraZeneca AB (SE) 2005-06-15 EP claimed
WO-2004016600-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-02-26 WO claimed
EP-1539723-B1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2006-05-24 EP disclosed
US-20060106015-A1 Novel use of benzothiazole derivatives ASTRAZENECA (SE) 2006-05-18 US disclosed
CN-1675189-A New use of benzothiazole derivatives ASTRAZENECA AB (SE) 2005-09-28 CN disclosed
EP-1539723-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016600-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106015-A1 Novel use of benzothiazole derivatives ITK, WEE2, WEE1 APP 3980/4885MAPT 3300/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.